Comparison of the Success Rate of Trabeculectomy with OculusGen versus Trabeculectomy with Mitomycin C

Purpose: To compare the effectiveness and safety of trabeculectomy with mitomycin C (MMC) versus trabeculectomy with OculusGen Methods: In this prospective study 14 eyes of 7 patients with a diagnosis of primary open angle glaucoma (POAG) that required trabeculectomy for both eyes were enrolled. For each patient we randomly performed trabeculectomy with MMC for one eye and trabeculectomy with subconjunctival OculusGen for fellow eye. Main outcome measures were: intraocular pressure (IOP), number of IOP reducing medications and surgical complications. Data analysis was performed using SPSS software version 15. Results: Mean age of the patients was 59±12.6 years. Mean duration of follow-up was 13±3.7 months for OculusGen group and 14.42±6.6 months for MMC group. Mean preoperative IOP was 19.14±3.8 mmHg with 3.14±0.37 number of medication and at last visit was 14.43±3.3 mmHg with 0.86±1.21 number of medication for OculusGen group. Mean preoperative IOP was 21.71±4.1 mmHg with 2.86±0.89 number of medication and at last visit was 12.29±3.5 mmHg with no medication for MMC group. The cumulative success at last visit was 100% in MMC group and 71.5% in OculusGen group (P=0.008%). No systemic or ocular complications related to MMC or OculusGen were seen. Conclusion: Trabeculectomy with OculusGen is a safe procedure with IOP reduction, at least in short-term, comparable to trabeculectomy with MMC, but with significantly more requirements for IOP lowering medications.